Browse studies

Find your next paid study

1,001 recruiting studies matching your filters

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

First in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-10203, a PI3Kα:RAS breaker, alone and in combination with other ant…

Solid Tumor, AdultMetastatic Breast CancerAdvanced Breast Cancer+8 more

Estimated

~$10 – $8,750

TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)NCT06625775

Phase 3

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with che…

Pancreatic CancerPancreatic Cancer MetastaticPDAC+5 more

Estimated

~$10 – $8,750

Revolution Medicines, Inc.NCT07491445

Phase 3

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that …

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04181060

Observational

Addressing Health Literacy With a Tailored Survivorship Care Plan to Improve Access in Underserved African American Prostate Cancer Patients

This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in…

Localized Prostate CarcinomaOligometastatic Prostate CarcinomaStage IVB Prostate Cancer AJCC v8

Estimated

~$10 – $6,250

Emory UniversityNCT06674863

Phase 1

A Phase 1a/1b Multicenter, Open-label Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of PLN-101095 as Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors Who Have Disease Progression While on an Immune Checkpoint Inhibitor (FORTIFY)

This is a Phase 1a/1b, dose-escalation/expansion, consecutive-cohort, open-label study to evaluate the safety, tolerability, PK, PD, and preliminary evidence o…

Advanced or Metastatic Solid Tumor

Estimated

~$10 – $8,750

Pliant Therapeutics, Inc.NCT06270706

Collection of Blood From Patients With Prostate Cancer

Background: * It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but ge…

Cancer Of ProstateProstate CancerProstatic Neoplasms+2 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00923221

Phase 2

Stereotactic Body Radiation Therapy (SBRT) to Extend the Benefit of Systemic Therapy in Patients With Solitary Disease Progression

The purpose of this study is to see if using Stereotactic Body Radiation Therapy/SBRT to treat a single metastatic site where cancer has worsened may be an eff…

Oligometastatic Breast CarcinomaBreast CancerMetastatic Breast Cancer+3 more

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05534438

Phase 1

A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF 06821497 (MEVROMETOSTAT) IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC), CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refract…

Metastatic Castration Resistant Prostate Cancer (mCRPC)Small Cell Lung Cancer (SCLC)Follicular Lymphoma (FL)

Phase I Trial of DS-8201a (Trastuzumab Deruxtecan) in Combination With Neratinib in Solid Tumors With HER2 Alterations

This phase I trial tests the safety, side effects, and best dose of neratinib in combination with trastuzumab deruxtecan in treating patients with solid tumors…

Metastatic Malignant Solid NeoplasmMetastatic Pancreatic AdenocarcinomaStage III Pancreatic Cancer AJCC v8+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05372614

Observational

Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients

The purpose of this study is to examine which of four components of a digital health intervention using an App and Fitbit meaningfully contribute to increased …

Metastatic Breast CancerMetastatic Breast Cancer (MBC)Metastatic Breastcancer

Estimated

~$10 – $6,250

Northwestern UniversityNCT07840599

Phase 3

Randomized Phase III Trial of Pembrolizumab vs. Pembrolizumab/Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma With Platinum Refractory Disease

This phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell …

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hypopharyngeal Squamous Cell CarcinomaMetastatic Laryngeal Squamous Cell Carcinoma+18 more

Estimated

Phase 1

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for s…

Metastatic Castration-resistant Prostate Cancer

Estimated

~$10 – $6,250

University of Wisconsin, MadisonNCT07609225